Literature DB >> 22326143

Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.

Jinghong Kou1, Min Song, Abhinandan Pattanayak, Jeong-Eun Lim, Junling Yang, Dongfeng Cao, Ling Li, Ken-ichiro Fukuchi.   

Abstract

We evaluated the therapeutic efficacy of combined treatment of Aβ-immunization with simvastatin in an Alzheimer mouse model at age 22 months. DNA prime-adenovirus boost immunization induced modest anti-Aβ titers and simvastatin increased the seropositive rate. Aβ-KLH was additionally administered to boost the titers. Irrespective of simvastatin, the immunization did not decrease cerebral Aβ deposits but increased soluble Aβ and tended to exacerbate amyloid angiopathy in the hippocampus. The immunization increased cerebral invasion of leukocytes and simvastatin counteracted the increase. Thus, modest anti-Aβ titers can increase soluble Aβ and simvastatin may reduce inflammation associated with vaccination in aged Alzheimer mouse models. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326143      PMCID: PMC3298635          DOI: 10.1016/j.jneuroim.2012.01.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  80 in total

1.  Differential patterns of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 mRNA and protein levels in developing regions of rat brain.

Authors:  K P Das; S L Chao; L D White; W T Haines; G J Harry; H A Tilson; S Barone
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

Review 2.  Immunotherapeutic approaches to Alzheimer's disease.

Authors:  Alon Monsonego; Howard L Weiner
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

Review 3.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

4.  Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

Authors:  Alon Monsonego; Jaime Imitola; Sanja Petrovic; Victor Zota; Anna Nemirovsky; Rona Baron; Yair Fisher; Trevor Owens; Howard L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

5.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 6.  Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review.

Authors:  E Uro-Coste; G Russano de Paiva; C Guilbeau-Frugier; N Sastre; P J Ousset; N A da Silva; V Lavialle-Guillotreau; B Vellas; M-B Delisle
Journal:  Clin Neuropathol       Date:  2010 Jul-Aug       Impact factor: 1.368

7.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

8.  The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

Authors:  Christoph Wiessner; Karl-Heinz Wiederhold; Alain C Tissot; Peter Frey; Simone Danner; Laura H Jacobson; Gary T Jennings; Rainer Lüönd; Rainer Ortmann; Julia Reichwald; Mauro Zurini; Anis Mir; Martin F Bachmann; Matthias Staufenbiel
Journal:  J Neurosci       Date:  2011-06-22       Impact factor: 6.167

9.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

10.  Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

Authors:  Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Dora Games; Peter Seubert; Dale Schenk; Bradley T Hyman
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more
  4 in total

Review 1.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer's disease: prophylactic and therapeutic applications.

Authors:  Jinghong Kou; Junling Yang; Jeong-Eun Lim; Abhinandan Pattanayak; Min Song; Stephanie Planque; Sudhir Paul; Ken-Ichiro Fukuchi
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

Review 3.  The role of cholesterol metabolism in Alzheimer's disease.

Authors:  Jia-Hao Sun; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-18       Impact factor: 5.590

4.  Efficacy and Safety of the Immunization with DNA for Alzheimer's Disease in Animal Models: A Systematic Review from Literature.

Authors:  Yandara Akamine Martins; Cristiane Jumko Tsuchida; Patrícia Antoniassi; Izabel Galhardo Demarchi
Journal:  J Alzheimers Dis Rep       Date:  2017-12-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.